Evidence map›Paper›PMID 37363859›Full record

ArticleBlood2023

Antibody-mediated pathogenesis of chronic GVHD through DBY/HLA class II complexes and induction of a GVL effect.

Kento Umino, Kaoru Morita, Takashi Ikeda, Shin-Ichiro Kawaguchi, Takashi Nagayama, Shoko Ito, Daisuke Minakata, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano and 17 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Blood, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Neoself Antigens Presented on MHC Class II Molecules in Autoimmune Diseases.Advances in experimental medicine and biology · 2024
    Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 11 institutions in 1 country.

Kento UminoDivision of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Kaoru MoritaDivision of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.ORCID 0000-0003-2456-8189
Takashi IkedaDivision of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Shin-Ichiro KawaguchiDivision of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Takashi NagayamaDivision of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.ORCID 0000-0001-9959-2955
Shoko ItoDivision of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Daisuke MinakataDivision of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Masahiro AshizawaDivision of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Chihiro YamamotoDivision of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.ORCID 0000-0002-5333-8414
Kaoru HatanoDivision of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Kazuya SatoDivision of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.ORCID 0000-0003-2876-4224
Ken OhmineDivision of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Shin-Ichiro FujiwaraDivision of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Shun-Ichi KimuraDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID 0000-0001-9827-8526
Shinichi KakoDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Noriko DokiDivision of Hematology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.ORCID 0000-0002-8661-3179
Yukiyasu OzawaDepartment of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
Yasuo MoriHematology, Oncology & Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
Tetsuya EtoDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Nobuhiro HiramotoDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.ORCID 0000-0002-0472-6680
Hirohisa NakamaeDepartment of Hematology, Osaka Metropolitan University Hospital, Osaka, Japan.ORCID 0000-0003-4203-990X
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-6704-3633
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.ORCID 0000-0002-0393-4066
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Hideki NakasoneDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID 0000-0001-5812-9315
Satoko MorishimaDivision of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.ORCID 0000-0002-7391-4271
Yoshinobu KandaDivision of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan.
Jichi Medical University · JPAichi Medical University · JPHamanomachi Hospital · JPHiroshima University · JPJapanese Red Cross Nagoya Daiichi Hospital · JPKobe City Medical Center General Hospital · JPKyoto University · JPKyushu University Hospital · JPOsaka Metropolitan University · JPTokyo Metropolitan Komagome Hospital · JPUniversity of the Ryukyus · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic graft-versus-host disease (cGVHD) is a multiorgan syndrome with clinical features resembling those of autoimmune diseases. Thus, understanding commonalities in the pathophysiology of cGVHD and autoimmune diseases, such as the presence of disease-risk HLA alleles, is imperative for developing novel therapies against cGVHD. Alloantibodies against H-Y antigens encoded on the Y-chromosome are well-described risk factors for cGVHD in female-to-male transplantation. However, because H-Y antigens generally localize intracellularly in the male reproductive organs, how they emerge at affected organ levels remains elusive. Here, by analyzing nationwide registry data stratified per donor-recipient sex, we identified specific HLA class II alleles that contributed to susceptibility to male cGVHD after transplantation from HLA-identical female siblings (HLA-DRB1∗15:02: hazard ratio, 1.28; 95% confidence interval, 1.03-1.58; P = .025). Coexpression of HLA-DRB1∗15:02 efficiently transported full-length H-Y antigens, especially DBY, to the surface. The presence of alloantibodies against DBY/HLA class II complexes significantly predicted the occurrence of cGVHD (68.8% vs 31.7% at 1 year; P = .002). Notably, the ability of HLA class II molecules to transport and present DBY to alloantibodies was closely associated with the susceptibility of HLA class II alleles to cGVHD. DBY specifically colocalized with HLA class II molecules on the dermal vascular endothelium in cGVHD and provoked complement-dependent cytotoxicity. Moreover, these complexes were observed in some male leukemic cells. Altogether, these findings suggest that vascular endothelial cells facilitate alloantibody-mediated cGVHD and highlight that alloantibodies against DBY/HLA class II complexes could be common targets for cGVHD and a graft-versus-leukemia effect.

Indexed as

Bronchiolitis Obliterans SyndromeGraft vs Host DiseaseHematopoietic Stem Cell TransplantationEndothelial CellsFemaleHLA-DRB1 ChainsHumansIsoantibodiesMaleProteinsHLA-DRB1 ChainsIsoantibodiesProteins

Identifiers

PMID37363859
OpenAlexW4382056346

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.